Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism by Kabashima, Kenji et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 12,  November 27, 2006  2683–2690  www.jem.org/cgi/doi/10.1084/jem.20061289
2683
Although most antibody responses are initiated 
in secondary lymphoid organs, long-lived IgG-
secreting plasma cells are located predominantly 
in the BM (1–3). The homing of IgG plasma-
blasts and plasma cells (hereafter referred to in 
combination as antibody-secreting cells [ASCs]) 
to the BM occurs only gradually and to a low 
level in the primary response but is rapid in the 
secondary response (1, 4). Studies with non-
replicating antigens showed that ASCs were 
abundant in blood at day 3 of the secondary re-
sponse but were few in number by day 7 (5, 6). 
Splenectomy at day 2 of the secondary re-
sponse to sheep red blood cells (SRBCs) largely 
prevented ASCs from appearing in the BM, 
whereas splenectomy at day 4 had little impact 
on the number of BM ASCs (7). IgG ASCs in 
blood affi   nity mature in parallel with BM ASCs, 
supporting the view that blood ASCs are in 
transit to the BM (8).
Homing of ASCs to the BM is in part de-
pendent on the chemokine receptor CXCR4 
(9–11). The CXCR4 ligand, SDF-1 (CXCL12), 
is abundantly expressed in the BM and is also 
strongly expressed in the red-pulp (RP) of spleen 
and in the medullary cords in LNs (6, 12). 
ASCs that lack CXCR4 fail to localize appro-
priately in the splenic RP and LN medullary 
cords and fail to accumulate to normal num-
bers in the BM (6, 9). However, CXCR4-
  defi  cient ASCs are found in elevated numbers 
in the blood, indicating that this receptor is not 
essential for the cells to egress from secondary 
lymphoid organs (6).
Recent studies have identifi  ed an impor-
tant role for sphingosine-1-phosphate (S1P) 
receptors in lymphocyte egress from secondary 
lymphoid organs. Initial studies with the immuno-
suppressant compound, FTY720, showed that 
it inhibits lymphocyte egress from LNs and 
Peyer’s patches (13). The eff  ects of FTY720 
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on egress from the spleen have been diffi   cult  to  assess 
  because cell entry and exit both occur via the blood. After 
injection, FTY720 is rapidly phosphorylated and FTY720-P 
is a ligand for S1P receptors 1, 3, 4, and 5 (14, 15). SIP 
receptor 1 (S1P1) is essential for blood vessel development, 
and mice lacking this receptor die at embryonic day 13.5–
14.5 (16). Studies in fetal liver chimeras or in tissue-specifi  c 
knockout mice showed that T cells lacking S1P1 are un-
able to exit the thymus, and S1P1-defi  cient B and T cells 
are ineffi   cient in exiting secondary lymphoid organs (17, 18). 
S1P is abundant in circulation and low in secondary lym-
phoid organs, and lymphocytes are thought to egress in re-
sponse to S1P (19). FTY720 treatment was not found to 
aff  ect the antibody response to lymphocytic choriomeningi-
tis virus or vesicular stomatitis virus (20), whereas in a recent 
study it reduced both the splenic and BM ASC response 
to 4-hydroxy-3-nitrophenyl-acetyl coupled to chicken 
γ-globulin (NP-CGG) in alum (21). However, the infl  u-
ence of FTY720 or S1P1 on ASC egress from lymphoid 
organs has not been directly assessed. Since ASCs down-
regulate expression of CXCR5 and CCR7 and migrate to 
splenic RP and LN medullary cords—egress sites from these 
organs—in a CXCR4-dependent manner, it has been un-
clear whether they will use the same egress mechanisms as 
naive lymphocytes.
Here we have examined the possibility that diff  erential 
S1P1 expression contributes to promoting release versus re-
tention of ASCs in secondary lymphoid organs. We show 
that FTY720 treatment inhibits IgG ASC egress from spleen 
and LNs. Using a mixed chimera approach we provide evi-
dence that S1P1 is required in B lineage cells for IgG ASC 
egress from the spleen and accumulation in the BM. In the 
secondary response, day 3 but not day 5 splenic ASCs and day 
3 blood ASCs demonstrate responsiveness to S1P, and blood 
ASCs express higher amounts of S1P1 than splenic ASCs. 
Blood ASCs are also found to have reduced CXCR4 expres-
sion compared with splenic ASCs, and they express higher 
amounts of Kruppel-like factor (KLF)2, a regulator of S1P1 
transcription. These fi  ndings suggest that diff  erential S1P1 
expression is a control point for secondary lymphoid organ 
retention versus egress into circulation and subsequent BM 
homing of newly developing IgG ASCs.
RESULTS
FTY720 treatment inhibits IgG ASC entry into blood 
and homing to BM
To test the impact of FTY720 treatment on ASC homing 
during the primary response, mice were immunized with the 
T cell–dependent antigen, NP-CGG in the adjuvant alum, 
and then at day 4 and 7 with FTY720. The frequency of 
ASCs in spleen and BM was then determined at day 7 and 10 
(Fig. 1 A). The FTY720 treatment was delayed until day 4 
to limit eff  ects on the initial recruitment of recirculating an-
tigen-specifi  c B and T cells. The IgG ASC frequency in the 
spleen was little aff  ected by the FTY720 treatment (Fig. 
1 A). In contrast, there was a decrease in the number of IgG 
ASCs in the BM at day 7 and 10 (Fig. 1 B). Similarly, s.c. 
immunization led to appearance of IgG ASCs in the draining 
LNs, and FTY720 treatment did not greatly aff  ect this re-
sponse. However, FTY720 largely inhibited the appearance 
of IgG ASCs in the BM after s.c. immunization (Fig. 1, 
A and B).
Eff  orts to determine whether there was an eff  ect on ASC 
egress from lymphoid organs into the blood were hampered 
Figure 1.  Antigen-specifi  c IgG1 ASC numbers in spleen, LNs, BM, 
and blood after immunization and FTY720 treatment. Spleen or LN 
(A), BM (B), and blood (C) cells were isolated at the indicated days after 
primary (1°) or secondary (2°) i.p. or s.c. immunization with NP-CGG in 
alum. Secondary immunizations were given 3–4 wk after the primary. 
P indicates samples taken just before the secondary immunization. FTY720 
(FTY(+)) or saline (FTY(−)) treatment was at day 4 and 7 after the pri-
mary or day 1.5 after the secondary immunization. ASC frequencies were 
measured by anti–NP-ELISPOT assay. The bars represent mean (± SD) 
number of ELISPOTs per organ or per ml of blood from at least three mice 
per group, and the data are representative of three experiments. The 
dashed line in the center panel of B indicates the baseline IgG1 ELISPOT 
frequency as a result of the primary immunization. (D) Percent of i.v. 
transferred ASCs that homed to the BM after 1 d in recipients treated 
3 h before cell transfer with saline or FTY720. Donor cells were spleno-
cytes from mice at day 3 of the secondary response. IgG1 ASC numbers 
determined by anti–NP-ELISPOT, and each point indicates an individual 
recipient. Student’s t test was performed between the indicated groups. 
*, P < 0.05.JEM VOL. 203, November 27, 2006  2685
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by the low numbers of ASCs entering into the blood during 
the primary response. We therefore performed secondary 
immunizations, treating the mice with FTY720 at day 1.5 af-
ter secondary immunization since BM homing via the blood 
occurs by day 3 of the secondary response (7). Again the 
treatment had little eff  ect on the IgG ASC number in the 
spleen (Fig. 1 A). A baseline of NP-specifi  c IgG ASCs were 
detected in the BM because of the primary immunization, 
but the number was increased twofold by day 3 and four- to 
fi  vefold by day 7 in the control group. FTY720 treatment 
inhibited the increase in BM ASC number (Fig. 1 B). IgG 
ASCs were readily detectable in the blood of control mice at 
day 3 and were largely gone by day 7 (Fig. 1 C). In contrast, 
few if any IgG ASCs appeared in the blood of FTY720-
treated mice (Fig. 1 C). We also asked whether FTY720 
could aff  ect BM homing after ASCs had entered the blood, 
by adoptively transferring spleen cells from mice at day 3 of 
the secondary response into unimmunized recipients that 
were either untreated or treated 1 d before with FTY720. 
ELISPOT analysis 1 d after transfer revealed similar numbers 
of donor-derived NP-specifi  c ASCs in the BM of control 
and FTY720-treated mice (Fig. 1 D). Thus, FTY720 treat-
ment inhibits the migration of IgG ASCs from spleen into 
blood but does not inhibit the homing of adoptively trans-
ferred IgG ASCs from blood to BM.
Intrinsic S1P1 requirement for BM homing
S1P1 is abundant in naive lymphocytes and is required in 
these cells for egress from lymphoid organs (17, 18). S1P1 is 
also abundant in endothelial cells (22). The ability of FTY720 
to inhibit cell egress from lymphoid organs may be caused by 
agonistic eff  ects on endothelial cells, down-modulation of re-
ceptors on immune cells, or disruption of S1P gradients (23–
25). To test whether there was an intrinsic requirement for 
S1P1 in ASCs for egress we reconstituted lethally irradiated 
Ighb mice with S1P1
−/− Igha fetal liver cells and small num-
bers of Ighb WT BM cells as a source of WT T cells. After a 
6-wk reconstitution, the mice were primed and then boosted 
with NP-CGG in alum. In mixed chimeric animals that 
mounted similar day 3 splenic IgG ASC responses (Fig. 2 A), 
very few S1P1
−/− ASCs could be detected in the BM at day 
3 or day 7 (Fig. 2 B). Consistent with S1P1 being required for 
ASC egress from the spleen, very few IgG ASCs could be 
detected in the blood at day 3, whereas IgG ASCs could be 
detected in the blood of WT chimeras (Fig. 2 C).
Immunohistochemical analysis revealed that the distribu-
tion of IgG ASCs in FTY720-treated mice at day 5 of the 
secondary response was similar to their distribution in saline-
treated controls (Fig. 3 A). Side-by-side comparison of the 
distribution of S1P1
−/− IgG1a and S1P1
+/+ IgG1b ASCs in 
the spleen of mixed chimeras further demonstrated that this 
Figure 2.  Intrinsic S1P1 requirement for IgG1 ASC egress into 
blood. Ighb mice reconstituted with a mixture of S1P1
−/− or S1P1
+/+ Igha 
fetal liver and WT Ighb BM were immunized with NP-CGG in alum, and 
IgG1a ASCs were measured 3 and 7 d later in spleen (A), BM (B), and blood 
(C). Data represent ELISPOTs per organ or per ml of blood in each animal, 
and bars show the mean ± SD from at least four mice per group com-
piled from three independent experiments. A Student’s t test was per-
formed between the indicated groups. *, P < 0.05.
Figure 3.  Normal ASC distribution in spleens of FTY720-treated 
WT mice and of S1P1
−/− plasma cells in mixed BM chimeras. 
Spleen sections from WT mice treated with or without FTY720 (A), and 
Igha S1P1
−/− fetal liver chimeric mice mixed with Ighb WT BM (B) immunized 
5 d earlier with NP-CGG in alum were stained with the indicated anti-
bodies (labels are the same color as the reaction product for that marker). 
Bar, 340 μm.2686  S1P1 AND PLASMA CELL EGRESS | Kabashima et al.
pathway is not required for positioning of IgG ASCs in clus-
ters within the RP (Fig. 3 B).
S1P responsiveness
As a read-out of S1P1 function we examined the ability of 
ASCs to migrate in response to S1P. We compared the re-
sponse of IgG ASCs from spleen at day 3 versus day 5 of the 
secondary response because previous studies have established 
that the majority of ASCs egress at day 3 with few cells con-
tinuing to egress into blood at day 5 (1). Day 3 but not day 5 
splenic IgG ASCs showed a small but signifi  cant (P < 0.05) 
chemotactic response to S1P (Fig. 4 A). ASCs at both time 
points demonstrated a similar responsiveness to SDF-1 (Fig. 
4 A). Consistent with previous demonstrations that high dose 
FTY720 treatment ablates S1P responsiveness in lymphocytes, 
cells from the treated mice had lost the ability to respond to 
S1P while continuing to respond to SDF-1 (Fig. 4 A). We 
also tested the ability of IgG ASCs from the blood to chemo-
tax to S1P. Two technical diffi   culties with this experiment 
were the very small numbers of ASCs present in blood and the 
presence of large amounts of S1P in blood that down-regulate 
and desensitize S1P1 (26). In preliminary experiments, we 
found it diffi   cult to wash the cells free of blood S1P. How-
ever, when the CD45.1 blood cells were mixed with a 10-fold 
excess of CD45.2 spleen cells at the time of isolation and 
washing and then the spleen cells depleted using antibodies to 
CD45.2, it was possible to reveal an S1P response in the blood 
cells, and this response exceeded that of spleen ASCs isolated 
in parallel and through the same steps (Fig. 4 B).
An assessment of the migratory response to S1P was also 
performed using cells from immunized Blimp1GFP reporter 
mice (27). Blimp1 is up-regulated at an early step in ASC 
diff  erentiation and is essential for plasma cell development 
and maintenance (28). As previously observed, the ASCs in-
duced in the spleen at day 3 of the secondary response were 
predominantly Syndecan1+ and GFPint (Fig. 5 A), whereas 
there was an accumulation of Syndecan1+ GFPhi cells at later 
time points (27). The ASCs in the blood at day 3 were con-
sistently Syndecan1+ GFPint, and very few Syndecan1+ GFPhi 
cells were detected (reference 27 and unpublished data). In 
migration assays, the splenic GFPint cells showed a migratory 
response to S1P, whereas the GFPhi cells showed little re-
sponse (Fig. 5, A and B). The splenic GFPint cells also showed 
a robust response to SDF-1 (Fig. 5, A and B). These fi  ndings 
confi  rm that the day 3 splenic ASC population contains S1P-
responsive cells.
Analysis of ASCs that accumulate in E- and P-selectin–
defi  cient mice showed that B220int/lo cells were more che-
mokine responsive than B220neg cells (29). Our observations 
agree with these fi  ndings because the migratory GFPint cells 
are B220int/lo, whereas the poorly migratory GFPhi cells ex-
press little if any B220 (Fig. 5 A, bottom and reference 27). 
In addition, within the GFPint population, we saw a trend to-
ward more S1P responsiveness in ASCs with higher amounts 
of B220 (Fig. 5 A, bottom). However, B220 levels were not 
markedly diff  erent between GFPint cells in spleen and blood 
(unpublished data). In the course of these experiments we 
observed that CXCR4 was expressed at intermediate levels 
on the surface of blood ASCs compared with splenic ASCs 
(Fig. 5 C). Despite the lower CXCR4 expression, the 
magnitude of the blood and splenic ASC SDF-1 chemotactic 
responses appeared similar (Fig. 4 B). A lack of direct correla-
tion between ASC CXCR4 levels and SDF-1 chemotactic 
responses has been observed previously (29–31).
S1P1 and KLF2 are more abundant in blood versus 
spleen ASCs
To measure S1P1 abundance in ASCs in blood versus spleen, 
Blimp1GFP reporter mice were primed and boosted with NP-
CGG and Syndecan1+ GFPint and GFPhi spleen cells or Syn-
decan1+ GFP+ blood cells were purifi  ed at day 3 of the 
response. The GFPint subset in the spleen was further divided 
into CXCR4hi and CXCR4int to explore the possibility that 
the CXCR4int population contained cells that were the most 
Figure 4.  Chemotactic response of IgG1 ASCs to S1P and SDF-1 
(CXCL12). (A) Spleen cells were prepared from mice 3 and 5 d after sec-
ondary immunization with or without FTY720 treatment. Input cells and 
cells that migrated to the lower well of a transwell chamber in the ab-
sence of chemokine (Nil) or in response to 1, 10, 100, or 1,000 nM S1P 
(left) or 0.3 μM SDF-1 (right) were analyzed by ELISPOT assay to detect 
IgG1-secreting cells. (B) Spleen and blood cells were prepared from mice 
3 d after secondary immunization as described in Materials and methods. 
Cells that migrated to the lower well of a transwell chamber in response 
to 0 or 100 nM S1P (left) or 0.3 μM SDF-1 (right) were analyzed by 
ELISPOT assay to detect IgG1-secreting cells. Bars represent means ± SD 
for six to eight samples from three experiments. A Student’s t test was 
performed between the indicated groups. *, P < 0.05.JEM VOL. 203, November 27, 2006  2687
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closely related to the blood ASCs (Fig. 5 C). Compared with 
naive B cells, GFPhi splenic ASCs had  20-fold reduced 
S1P1 transcript levels (Fig. 6 A). Splenic GFPintCXCR4hi 
cells also showed a marked reduction in S1P1 expression, 
whereas GFPintCXCR4int cells showed a trend toward in-
creased expression (Fig. 6 A). GFPint ASCs sorted from the 
blood had amounts of S1P1 that were within twofold of the 
levels detected in splenic B cells (Fig. 6 A). Expression of 
S1P2, S1P3, S1P4, and S1P5 in blood ASCs was low or un-
detectable (unpublished data). We also quantitated Blimp1 
transcripts and found that they were undetectable in splenic 
and blood B cells and abundant in the ASCs as expected 
(unpublished data). Finally, we examined the abundance of 
KLF2 (also known as lung KLF), a transcription factor that 
can promote S1P1 transcription (32, 33), and found that lev-
els were reduced in splenic GFPhi and GFPint CXCR4hi ASCs 
(Fig. 6 B). As for S1P1, KLF2 transcripts were more abundant 
in the splenic GFPintCXCR4int subset than in GFPintCX-
CR4hi cells and levels in blood GFPint ASCs were similar to 
splenic B cells (Fig. 6 B).
DISCUSSION
The above fi  ndings demonstrate that egress of IgG ASCs 
from secondary lymphoid organs into blood and BM is sensi-
tive to inhibition by FTY720 treatment and strongly depen-
dent on intrinsic S1P1 expression. S1P1 abundance and S1P 
responsiveness is found to be low in most splenic ASCs but is 
detectable within a Blimp1int CXCR4int splenic ASC popula-
tion and is most enriched in ASCs isolated from the blood. 
These fi  ndings establish an important role for S1P1 in IgG 
plasma cell homing and they suggest that diff  erential regula-
tion of S1P1 expression in diff  erentiating plasma cells may be 
a key factor determining whether they remain in secondary 
lymphoid organs or exit these organs to home to other sites, 
such as the BM. We also fi  nd diff  erential expression of KLF2 
between splenic and blood ASCs, pointing to a possible role 
for this transcription factor in defi  ning the gene expression 
program associated with the homing decision of diff  erentiat-
ing plasma cells.
In a previous study, treatment with FTY720 from the 
day of primary immunization was found to reduce the 
Figure 5.  Chemotactic response of Blimp1GFP/+ ASCs to S1P and 
SDF-1, and CXCR4 expression by spleen and blood ASCs. (a) Spleen 
cells were prepared from Blimp1GFP/+ reporter mice 3 d after immunization 
and applied to transwell chambers. Input cells and cells that migrated to the 
lower well of a transwell chamber in the absence of chemokine (Nil) or in 
response to 100 nM S1P or 0.3 μM SDF-1 were analyzed by FACS. Top plots 
show division of Syndecan+ GFP+ plasma cell into GFPint and GFPhi subsets, 
and numbers indicate the percentage of total cells in each gate. Bottom 
plots are pregated for Syndecan+ GFP+ cells (the combined GFPint and GFPhi 
gates in A) showing B220 versus GFP, and numbers show the percentage of 
cells in each quadrant. (B) Chemotactic response of splenic GFPint and GFPhi 
ASC subsets to S1P (left) and SDF-1 (right) are shown as the percentage of 
input that migrated. Bars show the mean ± SD from three experiments. 
Student’s t test was performed between the indicated groups. *, P < 0.05. 
(c) CXCR4 abundance on NP-specifi  c GFPint ASCs in the spleen and blood 3 d 
after secondary NP-CGG immunization. NP-specifi  c GFPint ASCs were iden-
tifi  ed as DAPI−CD4−CD8−NP+Syndecan+GFPint. The histogram plot shows 
the expression levels of CXCR4 on spleen and blood NP+GFPint ASCs.2688  S1P1 AND PLASMA CELL EGRESS | Kabashima et al.
magnitude of the IgG plasma cell and germinal center response 
(21). This may have been a consequence of reduced recruit-
ment of antigen-specifi  c T cells from other sites caused by 
the generalized block in secondary lymphoid organ egress 
(34). We delayed treatment of the mice for 4 d in the primary 
response or 1.5 d in the secondary response to provide an 
opportunity for recruitment of circulating antigen-specifi  c B 
and T cells, and we found that the secondary lymphoid or-
gan ASC responses were of similar magnitude in the treated 
and untreated groups, indicating that treatment did not se-
verely aff  ect the ability of the animals to mount an antibody 
response. In agreement with this conclusion, production of 
neutralizing antibodies after the fi  rst 3 wk of lymphocytic 
choriomeningitis virus and vesicular stomatitis virus infection 
were unaff  ected by low dose (0.3 mg/kg) FTY720 treatment 
(20). The ability of S1P1-defi  cient B cells to mount antibody 
responses also demonstrates that B cell expression of this re-
ceptor is not essential for B cell activation and diff  erentiation. 
However, because of limitations in the mixed fetal liver/BM 
chimera approach, our experiments have not examined the 
effi   ciency of each stage of the antibody and memory B cell 
response. Future experiments with mice carrying fl  oxed al-
leles of S1P1 (17) and B cell–selective Cre recombinase will 
be needed to more fully address the impact of ASCs and B 
cell S1P1 defi  ciency on maintenance of long-term antibody 
production and on B cell memory.
The mechanism by which FTY720 reduces lymphocyte 
egress from lymphoid organs is under active investigation 
(18, 35), and it has been debated whether FTY720 impacts 
lymphocyte egress from the spleen (14). Our fi  ndings here 
provide evidence that egress of IgG ASCs from the spleen 
can be inhibited by FTY720 treatment. Although the path-
way by which cells exit the spleen is not defi  ned, it is likely 
that the cells need to reach RP sinusoids to return to cir-
culation. Whether the ASCs that normally egress from the 
spleen correspond to cells that have fi  rst traveled into the 
RP is not yet clear. However, like spleen and LN ASCs, 
blood ASCs are found to have down-modulated CXCR5 
and CCR7 (and up-regulated CXCR4), making it likely 
that these cells migrate out of the white-pulp before exiting 
into circulation (6). The lack of CXCR5 and CCR7 expres-
sion on these cells but the continued requirement for S1P1 to 
permit effi   cient egress indicates that the intrinsic function of 
S1P1 cannot solely be to overcome the retention function of 
these chemokine receptors. However, it remains possible that 
CXCR4 normally participates in retaining cells in the spleen 
and LNs, and one function of S1P1 may be to overcome 
CXCR4-mediated retention. In this regard it is notable that 
the Blimp1GFP+ cells in the blood were CXCR4int compared 
with the bulk of the Blimp1GFP+ cells in the spleen. We pro-
pose that the reduced CXCR4 expression together with the 
increased S1P1 expression in a subset of cells contributes to 
shifting the balance of signals in favor of S1P1 and promoting 
egress. However, CXCR4 is only partially down-modulated, 
consistent with it also being required for lodgment of ASCs 
in the BM. Beyond this possible interplay, we anticipate that 
S1P1 will be required during egress to overcome additional 
retention signals, provide directional information, and/or 
promote reverse transmigration across blood or lymphatic 
vessels. Although we have focused on the mobilization of 
IgG ASCs to the BM, we anticipate that similar requirements 
will exist for IgA ASC egress from mucosal lymphoid tissues 
before their homing to epithelial surfaces.
Our fi  ndings suggest that defi  nition of the mechanism by 
which a subset of diff  erentiating ASC up-regulate S1P1 may 
illuminate how ASCs choose between the secondary lym-
phoid organ versus BM (or mucosa) tropic plasma cell fate. 
This cell fate decision may also encompass becoming short 
versus long lived, though some studies have indicated that 
long-lived plasma cells (PCs) are present in secondary lym-
phoid organs and BM (36) and, reciprocally, some of the PC 
homing to BM may be short lived. Although our studies 
show that S1P1 is necessary, our studies have not established 
Figure 6.  Quantitative PCR analysis of S1P1 and KLF2 mRNA from 
B cells and plasma cells in spleen and blood. Spleen cells from Blimp-
1GFP/+ mice 3 d after immunization were sorted into B220lo/− Syndecan+ 
GFPhi, GFPintCXCR4hi, and GFPintCXCR4int ASC subsets and B220+ Synde-
can− GFP− B cells. The CXCR4int gate was assigned based on CXCR4 levels 
on blood GFPint cells stained in parallel (see Fig. 5 C for an example). Blood 
B220lo/− Syndecan+ GFPint cells were from 3-d-immunized mice. The 
amounts of S1P1 (A) and KLF2 (B) mRNA were expressed as relative 
amount of the indicated mRNA normalized to HPRT. CXCR4 “total” indi-
cates the cells were isolated without gating on CXCR4 levels. Filled circles 
indicate individual samples, and bars represent the average. The data are 
pooled from three to four independent experiments. A Student’s t test 
was performed between the indicated groups. *, P < 0.05.JEM VOL. 203, November 27, 2006  2689
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that this receptor is suffi   cient to determine whether an ASC 
undergoes egress or is retained, and additional diff  erences be-
tween the cells may be important. The fi  nding that KLF2, a 
transcription factor shown to directly induce S1P1 expression 
in T cells (32, 33), is increased in blood Blimp1GFP+ cells is 
consistent with a role for this factor in promoting S1P1 ex-
pression in ASCs. KLF2 regulates the expression of additional 
genes in T cells (32, 33) and it may regulate expression of 
further genes involved in the commitment of diff  erentiating 
B cells to becoming BM tropic ASCs. Previous studies have 
suggested that BM tropic ASCs are induced predominantly 
from germinal center B cells or memory B cells (5, 37–39). 
Indeed, the synchronized wave of ASCs traveling through 
the blood at day 3 of the secondary response most likely re-
fl  ects rapid diff  erentiation of memory B cells into BM tropic 
ASCs. Although it is thought likely that these ASCs contrib-
ute to the pool of long-lived PCs, we have not established 
that this is the case for the cells tracked in the present study. 
Finally, although we were able to enrich based on intermedi-
ate CXCR4 and Blimp1GFP expression for splenic ASCs with 
an egress-related phenotype, this cell population had lower 
amounts of S1P1 and KLF2 than the cells isolated from blood, 
suggesting that we had only achieved partial enrichment. The 
future development of reagents that permit tracking of S1P1 
expression at the level of single B cells and ASCs should pro-
vide a method to isolate and further characterize the earliest 
cells that are taking on the BM tropic ASC fate.
MATERIALS AND METHODS
Mice and fetal liver chimeras. C57BL/6 (B6) and B6 CD45.1 mice were 
from the National Cancer Institute. Blimp1GFP/+ mice were generated as de-
scribed (27). S1P1
+/− mice (16) were crossed for at least fi  ve generations to B6 
or 129 mice, and then S1P1
+/− mice were intercrossed. S1P1
+/+ or S1P1
−/− 
fetal liver cells were prepared at embryonic day 12.5 and genotyped by PCR 
(16). Each preparation was mixed with B6 BM cells (1.5 × 105 and 3 × 106 
cells, respectively) and transferred to reconstitute three lethally irradiated B6 
CD45.1 mice (6). Mice were immunized 6 wk after reconstitution. For 
FTY720 treatment, B6 mice were injected i.p. with 3.0 mg/kg of FTY720 or 
with an equivalent volume of saline 4 and 7 d after primary and 1.5 d after sec-
ondary immunization. FTY720 was from a custom synthesis performed at SRI 
International. Animals were housed in a specifi  c pathogen-free facility and all 
experiments were in accordance with protocols approved by the University of 
California San Francisco Institutional Animal Care and Use Committee.
Immunizations. B6 mice were immunized with 50 μg of alum-precipi-
tated NP-CGG (Solid State Sciences) i.p. or s.c. in a volume of 200 μl. In 
some experiments, mice received a secondary immunization of the same 
type 3 wk later. Spleen, LNs, blood, and BM were harvested from mice at 
the indicated time points as described previously.
Flow cytometry and immunohistochemistry. Flow cytometric data 
were collected on a FACS LSRII (BD Biosciences) and analyzed using 
FlowJo software (Tree Star). Antibodies used were: biotin-conjugated anti-
CXCR4 (2B11; BD Biosciences), PE-conjugated anti-Syndecan (281–2; 
BD Biosciences), APC-conjugated anti-B220 (RA3-6B2; BD Biosciences) 
and NP (40), and APC-Cy7–conjugated anti-CD4 and CD8 (GK1.5, 53–
6.7; BD Biosciences). Streptavidin-PE–Cy5.5 was from Caltag, and DAPI 
was used to exclude dead cells. Spleens of immunized B6 mice treated with 
or without FTY720 were frozen in Tissue-Tek OCT compound (Baxter 
Scientifi  c). Cryostat sections (7 μm) were fi  xed in acetone and stained as de-
scribed previously (41) with sheep anti-IgD (Binding Site, Inc.) and biotin-
conjugated rat anti-IgG1, IgG1a, and IgG1b (MOPC-31C, 10.9, B68-2; BD 
Biosciences). Sheep antibodies were detected using HRP-conjugated don-
key anti–sheep IgG (Jackson ImmunoResearch Laboratories). Biotinylated 
reagents were detected using the SA-AP (Jackson ImmunoResearch Labora-
tories). Enzyme reactions were developed with conventional substrates for 
peroxidases (diaminobenzidine; Sigma Chemical Co.) and alkaline phospha-
tase (Fast Blue; Sigma Chemical Co.).
Cell sorting and quantitative PCR. Spleen cells from B6 mice and 
Blimp1GFP mice were stained, and ASCs and B cells were isolated with a 
MoFlo cell sorter (Cytomation). To isolate blood Blimp1GFP+ cells, blood 
from 15–20 mice at day 3 after secondary immunization was used for each 
experiment. In some cases, to generate enough mice bearing the Blimp1GFP 
allele in their hematopoietic cells, BM chimeras were made by transferring 
CD45.2 Blimp1GFP BM into irradiated CD45.1 B6 recipients and allowing 
6 wk for reconstitution before primary immunization. The purity of the 
sorted cells was typically >95%. RNA was prepared from sorted cells with 
RNeasy (QIAGEN), and cDNA was used for quantitative PCR on an ABI 
7300 sequence detection instrument (Applied Biosystems) using the follow-
ing primer and probe sets with AmpliTaq Gold DNA polymerase (Applied 
Biosystems) CXCR4, forward, C  G  G  C  T  G  T  A  G  A  G  C  G  A  G  T  G  T  T  G   and 
reverse, T C  T  C  C  A  G  A  C  C  C  C  A  C  T  T  C  T  T  C  A  ; probe FAM-C A  T  G  G  A  A  C  C-
G  A  T  C  A  G  T  G  T  G  A  G  T  A  T  A  T  A  C  A  C  T  T  C  T  G  A  -TAMRA; Blimp1(Prdm1): 
forward, G  G  A  T  C  T  T  C  T  C  T  T  G  G  A  A  A  A  A  C  G  T  G  T   and reverse, A  G  C  C  G-
T  G  T  A  A  A  G  T  A  G  A  C  T  G  C  C  T  T  G  ; probe FAM-T  A  C  G  A  C  C  T  T  G  C  C  A  A  A-
G  G  C  T  G  C  A  T  T  T  T  A  A  A  -TAMRA; and HPRT, S1P1, S1P2, S1P3, S1P4, 
and S1P5 as reported (18). KLF2 (and HPRT) was quantitated using SYBR 
Green (Bio-Rad Laboratories), and KLF2, forward, T  A  T  C  T  T  G  C  C  G  T  C  C-
T  T  T  G  C  C  A   and reverse, T  T  A  G  G  T  C  C  T  C  A  T  C  C  G  T  G  C  C   primers.
Chemotaxis assays. Cells were tested for transmigration across uncoated 
5-μm transwell fi  lters (Corning Costar Corp.) for 3 h to S1P (Sigma-Al-
drich), SDF-1 (PeproTech), or medium in the bottom chamber and were 
enumerated by ELISPOT or, in the case of cells from Blimp1GFP/+ mice, by 
fl  ow cytometry (42). To prepare blood cells for chemotaxis, 2 × 106 Ly5.1 
Igha RBC-lysed blood cells isolated by cardiac puncture were mixed with 
108 Ly5.2 Ighb RBC-lysed spleen cells, incubated for 30 min at 37°C in 
DMEM 0.5% fatty acid–free BSA, washed twice, and then the Ly5.1 and 
Ly5.2 cells were separated using Ly5.2 and AutoMACS. Because of the low 
frequency of ASCs, the blood cells that migrated across 8 transwells and the 
spleen cells that migrated across 4 transwells in response to S1P were pooled 
and tested in the ELISPOT or FACS assays.
ELISPOT assays. Freshly isolated spleen, blood, BM, and LN cells were 
used in ELISPOT assays as described previously (6). Plates were precoated 
with NP25-BSA (Solid State Sciences). IgM, IgMa, IgMb, IgG1a, IgG1b, and 
IgG were detected with anti–mouse IgM biotin (Caltag), IgMa biotin (DS-1; 
BD Biosciences), IgMb biotin (AF6-78; BD Biosciences), IgG1 biotin (BD 
Biosciences), IgG1a biotin (BD Biosciences), and IgG1b biotin (BD Biosci-
ences), followed by SA-HRP and True Blue (Kirkegaard & Perry Labs, Inc).
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